CODEXIS, INC. (CDXS) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.25

From 52W high−53.68%

Volume1.15M

Market cap$144.55M

P/E (TTM)—

P/S (TTM)1.9x

Div yield—

Key dataOct 19, 2026

Open

$1.25

From 52W high

−53.68%

Volume

1.15M

Market cap

$144.55M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.9x

P/E (TTM)

—

RSI (14)

47.1

MomentumView details →

1D Return

+6.45%

YTD Return

−17.18%

SummaryUpdated Jun 1, 2026

Codexis, Inc. (NASDAQ:CDXS) is a biotechnology company founded in 2002 and headquartered in Redwood City, California. The company went public in 2010 and specializes in developing engineered enzymes and proteins through its proprietary CodeEvolver protein engineering platform. Codexis has evolved from a broad enzyme development company to focus primarily on pharmaceutical manufacturing applications, particularly in the emerging field of small interfering RNA (siRNA) therapeutics production through its ECO Synthesis platform.

Ask drillr about CODEXIS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−7.9x

EV/Sales

2.1x

P/S (TTM)

1.9x

P/B (TTM)

4.4x

ProfitabilityView details →

Gross Margin

83.71%

Net Margin

−39.55%

EBITDA Margin

−26.60%

ROE (TTM)

−93.22%

ROA (TTM)

−25.59%

Asset Turnover

0.62x

GrowthView details →

Revenue YoY

+35.89%

EPS YoY

+59.53%

FCF YoY

+82.03%

Revenue CAGR 3Y

−20.22%

EPS CAGR 3Y

+43.82%

EBITDA YoY

+59.52%

MomentumView details →

1D Return

+6.45%

YTD Return

−17.18%

1Y Return

−50.73%

RSI (14)

47.1

vs 50D SMA

−7.17%

vs 200D SMA

−26.50%

Capital & dividendView details →

Debt/Equity

2.20x

Current Ratio

3.06x

Quick Ratio

2.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

8.24%

Beats (12Q)

7/12

Next Q EPS Est

−$0.06

Avg Surprise (4Q)

105.67%

Rev Surprise

4.05%

Financials snapshotView financials →

Revenue (TTM)

77.68M

Net Income (TTM)

−30.72M

Op. CF (TTM)

−10.40M

Next earningsNov 5, 2026 →

Latest newsMore news →

Codexis Inc. announced an agreement with an unnamed pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform.22d ago

Codexis reported financial results for the second quarter ended June 30, 2026, with revenue of $14.9 million.69d ago

Similar companies

Jyong Biotech Ltd. Ordinary SharesMENS Pyxis Oncology, Inc.PYXS Veraxa Biotech Holding AGVRXA Coherus Oncology, Inc.CHRS Molecular Partners AGMOLN Compass Therapeutics, Inc.CMPX Find similar companies →

Latest newsMore news →

Codexis Inc. announced an agreement with an unnamed pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform.22d ago Codexis reported financial results for the second quarter ended June 30, 2026, with revenue of $14.9 million.69d ago